The General Hospital Corporation

New England Medical Center Hospitals. Inc.

St IP Holding Ag

Boston Biocom LLC

Aperisys, Inc.

Jeffrey A Gelfand

Mark C Poznansky

Timothy Alan Brauns

Michael R Hamblin

Pierre R Leblanc

Liyi Huang

Svetlana E Korochkina

Daniela Vecchio

Giacomo Landi

Yingying Huang

Yoshinori Yamada

Bomi Framroze

Sara Pai

Stephen J McCormack

Huabiao Chen

Michael V Callahan

The invention relates to fusion proteins comprising an antigen binding domain fused with a modified heat shock 70 protein. The invention further relates to methods of using the fusion proteins to induce an immune response to antigens and to treat diseases associated With antigens.

Antigen-binding fusion proteins with modified HSP70 domains

The present invention relates to methods and compositions for treating human papilloma virus (HPV)-associated diseases using an inhibitor of CXCL12 signaling. The invention further relates to methods and compositions for treating immune checkpoint blockade resistant diseases using an inhibitor of CXCL12 signaling. The invention further relates to methods and compositions for enhancing the immune response against an HPV-associated disease using an inhibitor of CXCL12 signaling.

CXCR4/CXCR7 blockade and treatment of human papilloma virus-associated disease

This disclosure is directed to immune treatment of a disease (e.g., an infectious disease) using a fusion protein in combination with an anti-chemorepellant agent. In particular, the fusion protein comprises an antigen-binding domain (e.g., an antibody or antibody fragment) and a stress protein domain.

HSP fusion protein with anti-chemorepellant agent for treatment of infectious disease

This disclosure is directed to methods of preparing dendritic cells or other CD40 bearing antigen-presenting cells and methods of treating cancer by using the dendritic cells or other antigen-presenting cells in combination with anti-chemorepellant agents. This disclosure is further directed to methods of preparing T cells and methods of treating cancer, by activated T cells optionally in combination with anti-chemorepellant agents. The antigen presenting cells of the disclosure are activated by incubation with cancer cells and fusion proteins. The T cells of the disclosures are activated by incubation with activated antigen-presenting cells that were activated by incubation with cancer cells and a fusion protein. In particular, the fusion protein comprises an antigen-binding domain, e.g., an antibody or antibody fragment, and a stress protein domain.

Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer

This disclosure is directed to immune treatment of a disease (e.g., cancer) using a fusion protein in combination with an anti-chemorepellant agent. In particular, the fusion protein comprises an antigen-binding domain (e.g., an antibody or antibody fragment) and a stress protein domain.

HSP fusion protein with anti-chemorepellant agent for treatment of cancer

A problem of incomplete inhibition of harmful cells/bacteria and short duration of time, after the photodynamic treatment, during which such cells may re-grow, is solved by exposing the target bacteria with a multi-component photosensitizer material formed by adding a predetermined potentiating chemical to a conventional single-component photosensitizer at the target, prior to irradiating the target with light. The multi-component photosensitizer is effectuated by forming a mix of the two chemical compositions or by sequential exposure of the bacteria to a single-component photosensitizer and the potentiating chemical of choice.

Antimicrobial photodynamic inactivation procedure and system

This disclosure provides, among other things, formulated oltipraz compositions comprising stabilized oltipraz crystals, for use in treating a patient who has a viral infection or is at risk of incurring a viral infection. Such viral infections can include a viral infection caused by a coronavirus such as one associated with MERS or SARS, e.g., SARS-CoV-2.

Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione

Provided herein are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to four biotinylated components, and further wherein at least two of the four biotinylated components are not identical.

Immunotherapies employing self-assembling vaccines

System and method for photo-dynamic procedure

The invention relates to fusion proteins comprising a stress protein fused with an engineered antibody or fragment that binds to mesothelin, or a stress protein fused with a biotin-binding protein in combination with a biotinylated engineered antibody or fragment that binds to mesothelin. The invention also relates to fusion proteins comprising a stress protein fused with an antibody binding protein in combination with an engineered antibody or fragment that binds to mesothelin. The invention also relates to fusion proteins comprising an engineered antibody or fragment that binds specifically to mesothelin fused in frame with a biotin binding protein. The invention also provides fusion proteins comprising an engineered antibody or fragment, that binds to mesothelin, fused with an antibody binding protein. The invention also relates to methods of using fusion proteins of the invention to induce an immune response to mesothelin and to treat disease.

Mesothelin antibody protein fusions and methods of use

Provided are fusion polypeptides comprising an engineered antibody and a stress protein that bind to antigens with high affinity, are highly immunogenic, exhibit MHC class I priming and are able to be produced in non-mammalian cells, such as

Engineered antibody-stress protein fusions

Mass medical, e.g., cervical cancer, screening is provided to areas of the world where a lack of sufficient laboratory infrastructure and technical skills presently compromises the effectiveness of screening or even makes mass screening impossible. These methods are cost-effective and provide excellent sensitivity and specificity in cervical cancer screening.

Growing community of inventors

Cambridge, MA, United States of America

Jeffrey A Gelfand